Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks Bruce. I had not seen nor had I heard that before.
I think you misunderstand. I love Mayo and the research they do and I am not trying to expedite anything they are doing. I just don't think "soon" (that's a tpiv company word) has any meaning. In my opinion, you should too. There is no need to defend the company here.
Or is it the longer we are kept in the dark, the better?
So, the best we know, PH1 final results could be reported after next May or June, or beyond if trials are extended. As I recall, Mayo has not said anything about when results would be given. Why am I believing this was to be soon?
With the primary completion dates of NCT01606241 and NCT00640861 having been changed from 2016 (no data reported) to 2017 (no data reported), and now to 2018 (no data reported so far), why are we thinking we will get data soon? Isn't it way past soon? I'm beginning to feel toyed with.
It would be nice if there were some high notes in DR Knutson's keynotes in Boston today.
I seem to remember him being listed as one of many speakers. Now, he is not. That's all I know.
In my view, cancelling SABCS visit means it was more than just an educational visit, as some have suggested. We will know soon.
So why has Dr Knutson cancelled his involvement at SABCS in Dec. (I can now find no agenda listing for him), and become the keynote speaker at C.H.I. in 2 weeks?
This new approach by TPIV could stir AZN's interest since their LYNPARZA seemed no match for NIRAPARIB, as it is only for use on 15 to 20% of patient population.
Tesaro's niraparib is in PH3 and in pill form. It has shown good results. TPIV200 vaccine could become a better choice if it proves to be a lot less expensive. Are vaccines significantly cheaper than pills?
I am not sure we should be probing TPIV officials to provide information MAYO may consider private. Their contract may address that. Just my opinion!
Thanks Tui. Did not know that TPIV200 had potential as treatment for non small cell lung cancer.
Clinical trial for NCT01606241 had 24 patients enrolled. Trial NCT 00640861 had 45 enrolled. I'm not sure what happened to NCT01632332, it had 24 enrolled and may have become part of another study. There may have been dropouts.
I am failing to find any recent news concerning TPIV's trial with AZN. As to Mayo's PH 1 final data, I still think it could be the answer to a lot of questions about its long term viability. If it works long term, it may be considered the best choice for any antigen presentation...and the closest way to see revenue which is what we could use right now. Just my opinion.
It might help to go way back to RKMaters post 16996, a comment about Herceptin and Mark Reddish's white paper "Tapimmune's Approach To A Her-2/Neu Therapeutic Vaccine". Are we beginning to see inabilities of trials to perform well without CD4 helper T-cells? Awaited TAP trials could soon answer that.
Thanks for the comment Dodger1. It may seem confusing, like two basketballs on the court. Thing is, they're both shooting for the same goal.
When you asked about ACCRU, I searched their website and found their spring news letter.It mentions their 280 patient ph 2 study assigned to them by Mayo clinic. I wasn't aware of this start up. Anyway, I figure DCIS trials would be done by them also. http://www.mayo.edu/pmts/mc5700-mc5799/mc5724-01.pdf
I'D like to see a couple of phase 2 trials started by ACCRU this month.
Just my opinion. If final ph 1 data is very significant, it could be delayed until SABCS in December. If the data is average positive, we should see the data soon. Hints from the company say positive and soon. I not sure the sp will move much on that kind of news. I think extending the trials a year was a positive thing. It tells me that there are still healthy patients. Also, its kinda like Mayo may be ironing out the wrinkles to give this a good show.
Maybe the next time TPIV needs money, it will be for production.
Was the abstract submitted by the deadline? to whom?...will we hear by December?
Results of NCT 00640861 should be interesting. It is a randomized, 45 patient, trial (with grant) for treating patients with stage II or stage III, breast cancer. I think this study is now called TPIV 100. The Mayo clinic began recruiting on 8/31/08. It became active not recruiting on 11/19/2010. Its primary completion date was extended to May/2017. I am hoping all patients eventually received the real dose, and disease free survival is very high. It certainly would be good news for us investors as well. I believe Mayo has 1 year to report this. I hope its next week.
I'M not so concerned about price dip. Its just that silence on this board suggests to me, after a company official leaves, that this board could reinforce the product better and not leave doubt about whether its effectiveness still remains the same. I know nothing about warrants. but I try to know as much about product as I possibly can. I rely on this board for some of that. Just keep up the good work, even during times like these...and believe me, I have lots of patience on this one.
I was thinking more that others on this board had lost confidence. Lack of discussion can mean there is disappointment somewhere.
Now that's what I'm talking about! Tell me about it. There is among them DCIS, possibly starting up in July which, in my opinion, should recruit quickly. We should be satisfied. I'm buying on the dips.
Its difficult to remain gutsy about this stock when those here who have supported it for years have suddenly gone silent. Do we no longer have the promise that we thought we had?
Surviving patients 6 mo after first patient recruited (not "active not recruiting")could be 5 yrs.. Sorry.
I am not sure which trials Dr Wilson was referring to in one of his interviews when discussing overall survival, in which he stated "we went out almost two years after the vaccine treatment and we intend to publish these results soon". If its ph 1, open label, trial NCT 01606241 (now TPIV 200),that trial began recruiting 7/25/12, became "active not recruiting" 1/21/14. Last patient/last dose (a 6 mo treatment) would be about 6/2014. The primary completion date is June, 2017. Surviving patients since LP/LD could be about 3 years. Surviving patients 6 mo after "active not recruiting" could be going on 5 years. Just using the numbers to make these assumptions. Better do your own DD.
Thank you Phantom Lord. The joint trial with AstraZeneca just may be timely enough, but share price could take a pounding in the mean time. Anything in between sure would help.
It is phase 2, but does it have long term value. That confuses me.
Which do you consider more important, Mayo data forthcoming or TPIV interim data?
Its the Mayo data I am more concerned about, and that just seems so slow.
OXIS uplisted to the OTCQB on Jan. 15, 2015., but that is not my point. TPIV, so far, has failed to convince investors of long term effects of any of its products. I believe that's the catalyst we need.
I was referring to the difficulty a company can have without data. OXIS is trading at near .05 a share. If they are still listed , they will not be there for long. Just my opinion.
OXIS did a reverse split, made it to the NASDAQ about a year ago. last time I looked, they were in the pennies again.
Without data, will we follow the same path as OXIS?
Thanks Mod. I'm new here, and like your info. Some may call this a pig, but I think this little pig is going to market. Maybe very soon.
Lawyers suing company. Isnt that like taking money out of your own pocket?
If the movie "Jerry Macguire" were about bio stocks, Cuba gooding would be saying...Show me the data!!